Dergiler / European journal of rhinology and allergy (Online) / 2021 / Cilt: 4 - Sayı: 3

Cacosmia and Cacogeusia in Patients with Persistent Anosmia and Ageusia due to COVID-19

Sayfa
87–90
Yayın Tarihi
2022-10-12
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Further studies are required to reveal the underlying sensorineural pathol- ogy for the development of cacosmia and cacogeusia and treatment of these symptoms.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: The most frequent symptoms in COVID-19 infection are fever, cough, and fatigue.
📊
Temel Bulgular & Veri:Methods: One hundred and twenty patients presenting to our clinic with loss of taste and smell after COVID-19 infec- tion without subsequent improvement were examined in this study.
💡
Sonuç & Katkı:Further studies are required to reveal the underlying sensorineural pathol- ogy for the development of cacosmia and cacogeusia and treatment of these symptoms.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Objective: The most frequent symptoms in COVID-19 infection are fever, cough, and fatigue. Also, olfactory and gus- tatory disorders can be seen with the infection. Despite an abundance of studies reporting anosmia and ageusia, there are limited studies on the development of cacosmia and cacogeusia. This study aimed to contribute to the literature on this novel disease by reporting and evaluating cacosmia and cacogeusia patients. Methods: One hundred and twenty patients presenting to our clinic with loss of taste and smell after COVID-19 infec- tion without subsequent improvement were examined in this study. Cacosmia and cacogeusia subsequently devel- oped in 17 of these patients. Patients’ demographic characteristics such as age and gender, history of chronic disease, and smoking status were investigated. Laboratory tests and magnetic resonance imaging of the brain were performed. Results: Cacosmia and cacogeusia developed in 17 (14.1%) patients out of 120 patients who had persistent anosmia and ageusia after COVID-19. No significant difference was observed in terms of gender, but mean age was statistically significantly lower in the group developing cacosmia. Decreased olfactory bulb volume was observed in two patients, interpreted as secondary to the infection. Conclusion: Cacosmia and cacogeusia can develop in late COVID-19 and can significantly impair the quality of life of patients. There is no correlation between the severity of the disease and the rate of these symptoms. Currently, there is no efficient treatment for these patients. Further studies are required to reveal the underlying sensorineural pathol- ogy for the development of cacosmia and cacogeusia and treatment of these symptoms.

🔖

Bu Makaleye Atıf Yap

Atalay, F., Kars, A., Topal, K. (2022). Cacosmia and Cacogeusia in Patients with Persistent Anosmia and Ageusia due to COVID-19. European journal of rhinology and allergy (Online), Cilt: 4 - Sayı: 3, 87–90. https://ajindex.com/articles/511890

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (15)

  1. Pappa S, Ntella V, Giannakas T, Giannakoulis VG, Papoutsi E, Katsaounou P. Prevalence of depression, anxiety, and insomnia among healthcare workers during the COVID-19 pandemic: A systematic review and meta-analysis. Brain Behav Immun. 2020
  2. [CrossRef] 2. Krajewska J, Krajewski W, Zub K, Zaton ́ ski T. COVID-19 in otolaryngologist practice: A review of current knowledge. Eur Arch Otorhinolaryngol. 2020
  3. [CrossRef] 3. Rockx B, Kuiken T, Herfst S, et al. Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model. Science. 2020
  4. [CrossRef] 4. Zou L, Ruan F, Huang M, et al. SARS-CoV-2 viral load in upper respiratory speci- mens of infected patients. N Engl J Med. 2020
  5. [CrossRef] 5. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020
  6. [CrossRef] 6. Niazkar HR, Zibaee B, Nasimi A, Bahri N. The neurological manifestations of COVID-19: A review article. Neurol Sci. 2020
  7. [CrossRef] 7. Lovato A, De Filippis C. Clinical presentation of COVID-19: A systematic review focusing on upper airway symptoms. Ear Nose Throat J. 2020
  8. [CrossRef] 8. Sayin I, Yazici ZM, Oz F, Akgul A. Otolaryngology-head and neck surgery per- spective of COVID-19. Turkiye Klinikleri J Med Sci. 2020
  9. [CrossRef] 9. Hummel T, Whitcroft K, Andrews P, et al. Position paper on olfactory dysfunc- tion. Rhinol Suppl. 2017
  10. [CrossRef] 10. Leopold D. Distortion of olfactory perception: Diagnosis and treatment. Chem Senses. 2002
  11. [CrossRef] 11. Kano T, Kanda K. Development and validation of a chemotherapy-induced taste alteration scale. Oncol Nurs Forum. 2013
  12. 40(2):E79-E85. [CrossRef] 12. Tong JY, Wong A, Zhu D, Fastenberg JH, Tham T. The prevalence of olfactory and gustatory dysfunction in COVID-19 patients: A systematic review and meta-analysis. Otolaryngol Head Neck Surg. 2020
  13. [CrossRef] 13. Giacomelli A, Pezzati L, Conti F, et al. Self-reported olfactory and taste disor- ders in patients with severe acute respiratory coronavirus 2 infection: A cross- sectional study. Clin Infect Dis. 2020
  14. [CrossRef] 14. Bagheri SH, Asghari A, Farhadi M, et al. Coincidence of COVID-19 epidemic and olfactory dysfunction outbreak in Iran. Med J Islam Repub Iran. 2020
  15. Tsuruoka S, Wakaumi M, Araki N, Ioka T, Sugimoto K, Fujimura A. Comparative study of taste disturbance by losartan and pe